Full Press Release Details
IDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK.
IDYA
IDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK
Key Takeaway: IDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK
Price reaction · baseline $13.61 (2022-06-27 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close · peak
-3.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma